For­mer GSK can­cer R&D chief Pao­let­ti takes the reins at Gam­maDelta; Blue­print inks big Cam­bridge lease

→ Pao­lo Pao­let­ti, the for­mer pres­i­dent of GSK’s on­col­o­gy R&D group, has tak­en the helm at Abing­worth-backed Gam­maDelta Ther­a­peu­tics. “I’m ex­treme­ly ex­cit­ed to take on this role to fur­ther ad­vance the pi­o­neer­ing re­search on gam­ma delta (γδ) T cells of the com­pa­ny’s founders, Pro­fes­sor Adri­an Hay­day and Dr Oliv­er Nuss­baumer at King’s Col­lege Lon­don and the Fran­cis Crick In­sti­tute,” Pao­let­ti said in a state­ment. “The unique prop­er­ties of γδ T cells, cou­pled with the pro­pri­etary knowl­edge of the com­pa­ny of­fer great prospects for the de­vel­op­ment of in­no­v­a­tive im­munother­a­pies for many forms of can­cers, in­clud­ing sol­id tu­mours, and po­ten­tial­ly au­to-in­flam­ma­to­ry dis­eases.” Pfiz­er vet Na­tal­ie Mount joined the biotech as CSO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER